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PURPOSE. Ocular mucous membrane pemphigoid (OcMMP) is a rare autoimmune disorder
resulting in progressive conjunctival fibrosis and ocular surface failure leading to sight loss in
up to 50%. This study was designed to optimize an ocular surface sampling technique for
identification of novel biomarkers associated with disease activity and/or progressive fibrosis.
METHODS. Fifty-seven patients with OcMMP underwent detailed examination of conjunctival
inflammation and fibrosis using fornix depth measurement. Ocular surface impression
cytology (OSIC) to sample superior bulbar conjunctiva combined with flow cytometry (OSIC-
flow) profiled infiltrating leukocytes. Profiles were compared with healthy controls (HC) and
disease controls (primary Sjo¨gren’s syndrome, pSS). Thirty-five OcMMP patients were
followed every 3 months for 12 months.
RESULTS. Overall neutrophils were elevated in OcMMP eyes when compared to pSS or HC (109
[18%] neutrophils/impression [NPI]; 2 [0.2%]; 6 [0.8%], respectively [P < 0.0001]) and in
OcMMP patients with no visible inflammation when compared with HC (44.3 [7.9%]; 5.8
[0.8%]; P < 0.05). At 12 months follow-up, 53% of OcMMP eyes progressed, and this was
associated with baseline conjunctival neutrophilia (P ¼ 0.004). As a potential biomarker, a
value of 44 NPI had sensitivity, specificity, and positive predictive values of 75%, 70%, and
73%, respectively. Notably, eyes with no visible inflammation and raised conjunctival
neutrophils were more likely to progress and have a greater degree of conjunctival shrinkage
compared to those without raised neutrophils.
CONCLUSIONS. These data suggest that OSIC-flow cytometric analyses may facilitate repeated
patient sampling. Neutrophils may act as a biomarker for monitoring disease activity,
progressive fibrosis, and response to therapy in OcMMP even when the eye appears clinically
uninflamed.
Keywords: impression cytology, pemphigoid, progression, autoimmune disease, fibrosis and
neutrophils
Ocular mucous membrane pemphigoid (OcMMP) is anautoimmune disease characterized by recurrent blistering
of mucosal surfaces including the skin, typified in the eye by
conjunctival inflammation and aberrant tissue regeneration
involving excessive scar formation and sight loss in up to 50%
from limbal epithelial stem cell failure, corneal scarring, and
neovascularization.1 Ocular MMP is a rare disorder with a
minimum incidence estimated at approximately 0.8 to 1.6/
million/year2 and a mean age of onset of 65 years, but it may
occur with a more aggressive phenotype in younger patients,3
with up to 30% not responding to immunomodulatory therapy4
and 40% demonstrating progressive conjunctival fibrosis in the
absence of clinically detectable ocular surface inflammation
leading to delayed diagnosis.5
In acute disease, the inflammatory process in OcMMP is
manifest as conjunctival inflammation characterized by red-
ness, edema, limbitis, and pain to varying degrees.4,6,7 In this
situation, clinicians rely upon subjective clinical quantification
of disease activity (redness, edema, and so on), usually
arbitrarily (as no formal scales exist), into none, mild, moderate,
or severe to monitor inflammation and to guide immunosup-
pressive therapy.3,4 Unfortunately, conjunctival scarring fre-
quently progresses even when subjectively, the eye is visibly
uninflamed.4,5 This suggests either that there is a self-
perpetuating fibrotic process in the absence of inflammation
or, alternatively, that at a molecular level, persistent inflamma-
tion results in progressive conjunctival fibrosis. At present, no
biological test or marker exists to quantify the extent of
inflammation or detect significantly active inflammatory tissue
cascades that represent a prelude to conjunctival fibrosis and
ocular surface failure and that may facilitate development and
implementation of effective therapeutic protocols designed to
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successfully and effectively induce, consolidate, and maintain
disease remission.
The underlying disease process in OcMMP is driven by
autoantibodies against the hemidesmosome subunits (includ-
ing epiligrin [subunit of laminin 5], bullous pemphigoid
antigen 1 [BP230], and bullous pemphigoid antigen 2
[BP180]) at the basement membrane zone (BMZ).1 This in
turn leads to complement activation and the accumulation of
inflammatory cells in the stroma.8,9 The CD4þ infiltrate is
thought to be Th2 in phenotype, associated with activation of
TGF-b and IL-13.10,11 The differences in the cellular infiltrate
between clinically involved and seemingly uninvolved con-
junctival mucous membranes are, however, not fully under-
stood.8,9,12 While numerous in vitro and ex vivo studies have
been undertaken, a major limitation of these is that they
represent a ‘‘snapshot’’ of what is happening rather than
providing data on disease course that may guide therapeutics.
As longitudinal tissue sampling by repeated ocular mucosal
tissue biopsy is associated with the risk of precipitating or
aggravating disease,1 published studies to date are dependent
on utilizing tissue ‘‘surplus to clinical requirement,’’ that is, use
of residual tissue from diagnostic conjunctival biopsy material,
for investigative immunohistochemical cellular phenotyping
and quantification.
These technical issues may be overcome by the use of
conjunctival ocular surface impression cytology (OSIC) where-
by the suprabasement membrane epithelium and cells are
removed with a polyethersulfone filter. Ocular surface impres-
sion cytology is a simple minimally invasive test currently used
in clinical practice for the diagnosis of limbal epithelial stem
cell failure.13 When adhered cells are recovered and analyzed
by multicolor flow cytometry (OSIC-flow),14–16 the technique
provides a means to characterize the ocular mucosal cellular
response associated with progressive conjunctival fibrosis and
identify cellular subsets that may be associated with disease
activity and progressive fibrosis when clinical evidence of
inflammation has subsided.
In this study, we have used OSIC-flow cytometric analyses
to phenotype patients with OcMMP and compared them with
disease controls (primary Sjo¨gren’s syndrome, a condition
associated with slowly progressive conjunctival scarring) and
healthy age-matched controls. We have shown that the
conjunctival epithelial cellular infiltrate in OcMMP is charac-
terized by a significant increase in neutrophils at baseline and
decrease in the dominant CD8ab population. A direct
correlation between the neutrophil infiltrate and visible
clinical inflammation together with a persistent conjunctival
neutrophilia in clinically uninflamed eyes is seen, and this
perpetuates fibrotic signaling cascades as exemplified by
clinically measurable progression of fibrosis. Ocular surface
impression cytology is a simple repeatable technique that
allows monitoring of disease course. The presence of
conjunctival epithelial neutrophils may represent a disease
‘‘biomarker’’ in patients with OcMMP for the prediction of
disease progression and for gauging and optimizing effective
therapeutic protocols to prevent blinding scarring and ocular
surface failure.
METHODS
Study Subjects
Clinical data collection and patient sampling were undertaken
following ethical approval in accordance with the Declaration
of Helsinki (Birmingham East, North and Solihull Ethics
Committee: Inflammation in Ocular Surface Disease IOSD 08/
H1206/165, UKCRN 7448).
Fifty-seven patients with OcMMP were recruited from
patients presenting to the Ocular Surface Disease clinic at
the Birmingham and Midland Eye Centre (BMEC) over a 24-
month period. The median age was 72 (range, 49–97 years);
patients included 30 females (53%); 55 white, and 1 black as
defined by the U.S. Census Bureau criteria (http://www.
census.gov/topics/population/race/about.html [in the public
domain]), and 1 South Asian (Asian or Asian British as defined
by the UK Census 2011).17 Diagnosis of OcMMP was based on
clinical findings characteristic for the disease, namely, progres-
sive conjunctival cicatrization in the absence of other causes of
conjunctival scarring.18–22 If patients did not have a previous
positive tissue biopsy, a confirmatory perilesional conjunctival
and/or oral mucosal biopsy for direct immunofluorescence
was undertaken. A positive result was defined as linear
deposition of IgG, IgA, or complement (C3) along the BMZ.1
If typical clinical characteristics were evident, a negative result
did not exclude the diagnosis4,18–20 because of the recognition
of a subgroup of ocular patients who have ocular features
consistent with OcMMP but have a negative biopsy.2,19,21 In
accordance with the first international consensus, a positive
indirect immunofluorescence was not an essential requirement
for diagnosis.1
Cross-sectional comparisons were made with (1) a group of
healthy, age-matched controls (HC; n ¼ 21; median age 64
[range, 45–83 years]; 12 females; 14 white, 7 South Asian),
defined as subjects with no history or clinical evidence of
ocular, systemic inflammatory, or autoimmune disease (includ-
ing dry eye),22,23 contact lens wear, previous ocular surgery,
cataract surgery within 3 months, or use of topical ophthalmic
medication; and (2) a disease control group, primary Sjo¨gren’s
syndrome (pSS), an autoimmune disease characterized by dry
eye disease that is associated with a slowly progressive
cicatrizing conjunctivitis. Diagnosis of pSS was based on the
revised American–European Consensus Group (AECG) crite-
ria,24 and the group comprised 19 patients (18 female; median
age 64 [range, 56–79]; 18 white, 1 South Asian). There was no
significant difference in age among the three groups.
Thirty-five of the OcMMP patients from the cross-sectional
OcMMP cohort were enrolled for longitudinal follow-up with
data collected at 0-, 3-, 6-, 9-, and 12-month visits.
Disease Grading and Staging
LogMAR visual acuity (VA) was recorded and classified as good
(0.0–0.5) or in accordance with the WHO definitions of visual
impairment (0.5–1.0), severe visual impairment (1.0–1.3), and
blind (<1.3).
Disease activity was based upon the extent of conjunctival
inflammation after secondary causes of inflammation (infec-
tion, trichiasis, and so on) had been excluded: absent, mild,
moderate, or severe (severe defined as being inflamed in all
four quadrants, the presence of limbitis and/or conjunctival
ulceration).25 The absence of inflammation was defined as no
clinically identifiable conjunctival inflammation on slit-lamp
examination.4 The stage of disease was determined objectively
by using a validated fornix depth measurer (FDM) for the lower
and upper fornix.26 For comparison, the staging systems
described by Mondino and Brown27 ([I] 0%–25%, [II] 25%–
50%, [III] 50%–75%; 75%–100% loss of inferior fornix) and
Foster28 ([I] subconjunctival scarring and fibrosis, [II] fornix
foreshortening of any degree, [III] presence of any degree of
symblepharon end-stage cicatricial pemphigoid), and Tauber et
al.’s29 proposed staging system combined with the use of the
FDM for determining percentage shrinkage of the lower fornix
were used. Progression was defined as an increase in forniceal
shrinkage (1 mm or greater) or by Tauber staging. Immuno-
suppression strategies used a ‘‘stepladder’’ approach as
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previously described.3 Information regarding surgical and
therapeutic intervention was also recorded.
Sample Collection and Laboratory Analysis
Both eyes were clinically phenotyped and sampled.
Ocular Surface Impression Cytologic Sampling. Col-
lection of conjunctival cells was undertaken with autoclaved
Supor 200 polyethersulfone filters (0.2-lm membranes) (VWR,
Lutterworth, UK) divided into two semicircles (measuring 133
6.5 mm2 each).30 Conjunctival OSIC was performed with up to
four semicircle membranes per eye (equivalent to two full
impression circles) from the superior unexposed bulbar
conjunctiva using a sterile technique30 (Fig. 1A) and as
previously described by our group.15,16,31 Conjunctival cells
were recovered by gentle agitation and centrifuged (400g for 5
minutes), and the supernatant was discarded, leaving 10 lL,
which was resuspended in a further 90 lL RPMI:10% Heat
Inactivated Fetal Calf Serum (HIFCS) (to a total 100 lL) unless
otherwise stated. Cells were placed in 96-well plates for flow-
cytometric analysis.
Peripheral Blood. Peripheral blood was collected in EDTA
tubes and aliquoted at a volume of 1 mL, centrifuged, and
resuspended in 1:10 dilution of filter-sterilized red cell lysis
buffer (8.29 g NH4Cl [Sigma-Aldrich, Gillingham, Dorset, UK],
1 g KHCO3 [Sigma-Aldrich], and 37.2 mg EDTA [Sigma-Aldrich]
per liter distilled H2O). After 5 minutes at room temperature,
the suspension was diluted with up to 15 mL RPMI to block
further lysis. Following centrifugation, the pellet was resus-
pended in phosphate-buffered solution (PBS; Oxoid, Cam-
bridge, UK) at a concentration of 1 3 107 cells/mL and
aliquoted at a volume of 100 lL into individual wells.
Flow Cytometry. Flow cytometry was undertaken with a
Dako Cyan ADP High Performance flow cytometer (Beckman
Coulter, High Wycombe, UK). Multicolor cytometry compen-
sation was performed using cells or compensation beads
individually stained with each fluorochrome-conjugated
antibody. Compensation circumvents spectral overlap by
adjusting for false positives from other fluorochromes. This
is achieved by setting compensation levels for one fluoro-
chrome at a level commensurate with the background
fluorescence of another, for example, PE-Cy7 anti-CD56
versus PerCP Cy5.5 anti-CD4; the fluorescence intensity for
the positive population of CD56-stained beads/cells is
adjusted so that it is at the same median fluorescence as
background (for the PerCP Cy5.5 channel).
Cells (100 lL) were placed into 96-well plates (with a cell
count per well ranging from 23 105 to 13 106 for peripheral
blood mononuclear cells [PBMCs]) or 20 lL positive and
negative compensation beads. Cells were centrifuged for 4
minutes at 400g at 48C; the supernatant was removed and the
96-well plate gently vortexed. Cells were stained with surface
marker antibodies (made up in 50 lL at appropriate
dilutions) and incubated on ice in the dark for 20 minutes.
One hundred microliters Fluorescence-activated cell sorting
(FACS) buffer (PBS and 0.5% bovine serum albumin [BSA;
Sigma-Aldrich] was added to each well prior to further
centrifugation and removal of supernatant. Cells were
resuspended in 295 lL FACS buffer and 5 lL counting beads
(CALTAG/Invitrogen, Paisley, UK) (1002 beads/lL) buffer
prior to analysis. For dead cell exclusion, 30 lL Sytox blue
(Invitrogen, Paisley, UK) was added at a dilution of 1/800 to
the FACS tubes and incubated for 5 minutes prior to running
on the flow cytometer.
Cell-surface fluorochrome-labeled monoclonal antibodies
were employed in two panels. Panel 1 included mouse anti-
human CD45RO (FITC), cdTCR (phycoerythrin, PE), CD4
(PerCP Cy5.5), CD45 (allophycocyanin, APC), CD3 (Alexa
Fluor 780) (Ebioscience, Hatfield, UK); CD8a (Pacific Orange)
(Invitrogen); CD8b (PE Texas Red) (Beckman Coulter); CD56
(PE Cy7) (Biolegend, Cambridge, UK). Panel 2 included mouse
anti-human CD16 (FITC), CD45 (allophycocyanin), CD14
(Alexa Fluor 780) (Ebioscience); CD20 (Pacific Orange),
CD19 (PE Texas Red) (Invitrogen); CD138 (PerCP Cy5.5)
(BD, Oxford, UK), and CD11b (PE Cy7) (Biolegend). These
were titrated to determine the optimal concentrations.
Appropriate panels were applied to cells recovered from
conjunctival OSIC or peripheral blood. Gating strategies were
as previously described.15,16,31
Statistical Analysis
Data were collected on all eyes and comparisons were
undertaken between the worse-affected eye for cross-sectional
cohort analysis of inflammation and the better-seeing eye for
VA. Cross-sectional comparisons were undertaken by nonpara-
metric Mann-Whitney U test for two groups, the Kruskal-Wallis
test with Dunn’s post hoc analysis when comparing continu-
ous variables, for example, cell numbers or percentage for both
eyes. The Jonckheere-Terpstra test was used for ordered
groups.
Data for both eyes were used for progression in the
longitudinal cohort, as outcomes could be different for each
eye for an individual. Initial comparisons were undertaken by
nonparametric Mann-Whitney U test for two groups. If
differences using the Mann-Whitney U test were significant,
generalized estimating equations (GEEs) were employed when
using data for both eyes in order to determine correlation and
establish whether progression data for both eyes were
significant while taking the effects of correlation into
consideration. Normality was assessed using a Kolmogorov-
Smirnov test and data were log transformed where necessary.
Differences in progression were determined by the Wald v2
test. Differences in repeated measures were also determined by
GEE between the right and the left eyes. Overall difference
over time was examined by the Huynh-Feldt test in association
with repeated measures analysis of variance.
Receiver operating characteristic (ROC) curve analyses
were undertaken with sensitivity and specificity for the
neutrophil numbers and percentage together with positive
predictive values as previously described.32 Differences in
progression between noninflamed eyes were undertaken by
the Jonckheere-Terpstra test or the Fisher’s exact test.
Analyses were performed using IBM SPSS 19 (IBM Corp.,
Armonk, NY, USA) and Prism version 5.0 for Macintosh
(GraphPad Software, La Jolla, CA, USA). Statistical significance
was defined as P < 0.05.
RESULTS
Demographic Information
Demographic and baseline clinical details for OcMMP and pSS
(disease control group) are summarized in Tables 1 and 2,
respectively. The majority of patients with OcMMP were on
topical ocular surface therapy (glucocorticoids, preservative-
free lubrication) while only 5% (3/57) required topical
antiglaucoma medication. Fifty-three percent (30/57) were on
some form of systemic immunosuppression at recruitment to
the cross-sectional study. Of the 35 patients enrolled into the
longitudinal study, 16/35 (46%) were on immunosuppression
at baseline, but by 12 months follow-up, their requirement for
immunosuppression increased to 71% (25/35). After exclusion
of other causes of reduced vision (cataract, glaucoma, uveitis,
and optic neuritis; n¼ 10), logMAR VA in the better-seeing eye
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FIGURE 1. Ocular mucous membrane pemphigoid is characterized by raised conjunctival epithelial neutrophils. (A) Ocular surface impression
cytology was performed with four semicircle membranes per eye (equivalent to two full impression circles) from an anesthetized superior
unexposed bulbar conjunctiva. Semicircles were gently pressed in the conjunctiva for a few seconds and lifted with forceps. (B) Representative flow
cytometric plots demonstrating the gating strategy to determine conjunctival leukocytes from OSIC and peripheral blood. Live leukocytes were
identified by gating for CD45þ cells that were negative for the dead cell exclusion dye Sytox blue. Neutrophils were defined as CD45 intermediate,
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was measured at 0.0 to <0.5 in 91% (43/47), >0.5 to <1.0 in
4% (2/47), >1.0 to <1.3 in 0%, and >1.3 in 4% (2/47). Patients
with OcMMP had levels of dry eye disease comparable to the
pSS disease controls defined by tear film break up time (TBUT)
(OcMMP median 7 [range, 0–11] seconds versus pSS 5 [2–8]
seconds, P ¼ 0.09). Primary Sjo¨gren’s syndrome patients did
not receive glucocorticoids or cyclosporin A at the time of
sampling.
For the full cohort, at recruitment conjunctival inflammation
was present in 65% (37/57) of OcMMP patients, with the
remaining (35% [20]) having no visible conjunctival inflamma-
tion at baseline. Details of the severity of inflammation together
with the damage (scarring) indices derived from clinical data
recorded in validated clinical record forms (CRF) are outlined in
Supplementary Table S1. Median central lower fornix depth was
4 (range, 0–13) mm; the number of lower fornix symblephara
was 2 (0–6), with horizontal symblephara involvement 6 (0–30)
mm. Forty-three percent of eyes (49/114) were Mondino stage
III/IV and 96% (110/114) were Foster stage III/IV.
OSIC-Flow of the OcMMP Conjunctival Epithelium
Shows Predominant Neutrophils and an Increase
in the CD4:CD8 Ratio
Using gating strategies on cells recovered by OSIC-flow as
previously described,15,31 leukocyte profiles in OcMMP, pSS,
and HC were determined in the worst inflamed eye in the
OcMMP cohort and right eyes for both healthy (HC) and
disease control (pSS) groups. Neutrophils are shown in Figure
1B and lymphocytes in Figure 2A. While overall there was no
difference in the total number of leukocytes between groups
(Table 3; Fig. 1C), the most striking observation was a
significant elevation of conjunctival epithelial neutrophils
among patients with OcMMP (neutrophil number/impression
[NPI] ¼ 109, 18%) compared to both disease and HC groups
(pSS [1.8, 0.2%]; HC [5.8, 0.8%] [P < 0.0001]) (Table 3; Fig.
1C). While an expected preponderance of female patients was
seen in both the OcMMP and PSS cohort (Table 1), an effect of
sex on conjunctival neutrophilia was not observed (OcMMP:
males 11.5% [range, 0.2–83.7]; females 19.8% [0.1–86.7]; P
value 0.97; pSS 18/19 female, statistical analyses not possible).
Individual lymphocyte subset comparisons demonstrated
fewer T cells (CD3þCD56 live cells) as a total number and
percentage of lymphocytes in the conjunctiva of patients with
OcMMP (Table 3). In addition, the dominant CD8abþ
population was significantly lower in patients with OcMMP
(HC, 371 versus pSS, 445 versus OcMMP, 124; P ¼ 0.0001),
resulting in an increased percentage of CD4þ cells as a
proportion of T cells with a concomitant elevation in the
CD4:CD8 ratio in OcMMP compared to HC (0.15 vs. 0.4 vs. 0.5;
P¼ 0.003) (Fig. 2B). Despite an expected elevation in CD4þ T
CD14, CD16þCD11bþ granulocytes. (C) OSIC-flow of the OcMMP conjunctival epithelium showed predominant neutrophils compared to healthy
controls (HC) and primary Sjo¨gren’s syndrome (disease controls, pSS). (Comparisons were undertaken by comparing the most inflamed eye at
presentation in patients with OcMMP (n¼ 57) versus the right eye of HC (n¼ 21) and patients with pSS (n¼ 19). Three-group comparisons were
undertaken by the Kruskal-Wallis test (C) (NS, not significant; *P¼ 0.01–0.05; **P¼ 0.001–0.01; ***P < 0.001).
TABLE 1. Patient Demographics and Characteristics for the OcMMP
and pSS Cohorts at Baseline. Direct Immunofluorescence (DIF) and
Indirect Immunofluorescence (IIF) Refer to the Proportion of Patients
Who Demonstrated the Linear Deposition of Immunoglobulin G, A, or
Complement (C3) Along the Basement Membrane Zone (BMZ) or Had
Measurable Titers of Immunoglobulin in the Serum, Respectively
Patient Demographics and Characteristics OcMMP
Total no. of patients 57
Total no. of eyes 114
Male:female (% female) 27:30 (53)
Median age, y (range) 72 (48–97)
Median duration of symptoms to diagnosis,
mo (range) 30 (1–480)
Median duration of known disease at
recruitment, mo (range) 14 (0–152)
Diagnosis*
DIFþ 70%, 40/57
IIFþ† 30%, 17/57
Extraocular mucocutaneous involvement
All mucocutaneous tissues 42%, 24/57
Skin 40%, 23/57
Oral 40%, 23/57
pSS
Total no. of patients 19
Male:female (% female) 1:18 (95)
Median age, y (range) 64 (45–83)
Median duration of symptoms to diagnosis,
mo (range) 13 (4–35)
Median duration of known disease at
recruitment, mo (range) 6 (0–7)
Extraocular mucocutaneous involvement
All mucocutaneous tissues 100%, 19/19
Skin 16%, 3/19
Oral 100%, 19/19
* Four patients in total did not undergo a conjunctival biopsy.
† All patients who were IIF were also DIF positive. There were no
patients who were IIF positive in the absence of positive DIF studies.
TABLE 2. OcMMP Longitudinal Study Cohort Patient Demographics
and Characteristics: 35 Patients Were Followed Prospectively and
Underwent Clinical Phenotyping Together With OSIC Sampling at 0, 3,
6, 9, and 12 Months. Direct Immunofluorescence (DIF) and Indirect
Immunofluorescence (IIF) Refer to the Proportion of Patients Who
Demonstrated the Linear Deposition of Immunoglobulin G, A, or
Complement (C3) Along the Basement Membrane Zone (BMZ) or Had
Measurable Titers of Immunoglobulin in the Serum, Respectively
Patient Demographics and Characteristics OcMMP
Total no. of patients 35
Total no. of eyes 70
Male:female (% female) 17:18 (51)
Median age, y (range) 71 (53–83)
Median duration of symptoms to diagnosis,
mo (range) 24 (1–480)
Median duration of known disease at
recruitment, mo (range) 14 (0–152)
Biopsy*
DIFþ 74%, 26/35
IIFþ† 26%, 9/35
Extraocular mucocutaneous involvement
All mucocutaneous tissues 51%, 18/35
Skin 46%, 16/35
Oral 6%, 2/35
* Four patients in total did not undergo a conjunctival biopsy.
† All patients who were IIF were also DIF positive. There were no
patients who were IIF positive in the absence of positive DIF studies.
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cells in pSS as previously published,33 the CD4:CD8 ratio was
greater in OcMMP versus pSS (disease controls), although this
difference did not reach statistical significance. An elevation in
the percentage of CD8 abþ and double negative (CD8
abCD4) T cells was also observed. No changes in the B cell
or NK populations were seen, but a reduction in the Natural
Killer T (NKT) cell population was seen in OcMMP compared
to HC (Table 3).
There was no difference in the total number/percentage of
leukocytes (1579 vs. 2595; P¼ 0.18), monocytes (194 vs. 289;
P ¼ 0.51), and neutrophils (102 vs. 239; P ¼ 0.94) between
biopsy-positive (n ¼ 40) and -negative (n ¼ 17) OcMMP
patients. In addition, no differences in lymphocyte and
neutrophil populations were observed in the peripheral blood
of patients with OcMMP, healthy volunteers, and those with
pSS (lymphocytes [37% vs. 44% vs. 35%; P ¼ 0.2], neutrophils
[52% vs. 45% vs. 49%; P¼ 0.78]), although a difference in the
monocyte populations between the pSS and HC group was
observed (6% vs. 7% vs. 5%; P ¼ 0.04).
Neutrophils Are Detected in Clinically Uninflamed
OcMMP Eyes and Are Associated With the Grade of
Visible Conjunctival Inflammation
In clinically noninflamed eyes, the number and percentage of
neutrophils were significantly higher when compared to HC
44.3 (7.9%) vs. 5.8 (0.8%); P ¼ 0.02 and P ¼ 0.004 (Figs. 3A,
3B). This suggests that neutrophils are present even in the
absence of clinically manifest, that is, visible conjunctival
inflammation. Importantly, a direct association between the
FIGURE 2. Ocular mucous membrane pemphigoid is characterized by a reduction in the dominant CD8abþ T-cell population and elevation in the
CD4:CD8 ratio. (A) Representative plots demonstrating the gating strategy to determine conjunctival leukocytes from ocular surface impression
cytology (OSIC). Comparisons were undertaken by comparing the most inflamed eye in patients with ocular mucous membrane pemphigoid
(OcMMP, n¼ 57) versus the right eye of healthy controls (HC, n¼21) and patients with primary Sjo¨gren’s syndrome (pSS, n¼ 19) (B). Three-group
comparisons were undertaken by the Kruskal-Wallis test (NS, not significant; *P ¼ 0.01–0.05; **P ¼ 0.001–0.01; ***P < 0.001).
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neutrophil infiltrate number and percentage is seen across the
spectrum of clinical entities defined as a range from HC
conjunctiva, OcMMP conjunctiva with no visible inflammation,
and OcMMP conjunctiva with visible inflammation graded as
mild and moderate/severe (Fig. 3C: HC 5.8 [0.8%] versus
noninflamed OcMMP 44.3 [7.9%] versus mildly inflamed
OcMMP 94.3 [7.3%] versus moderately/severely inflamed
1912 [42.3%] [P < 0.0001]). These data confirm persistence
of inflammation occurring at a molecular level in eyes that are
clinically classified as uninflamed with no visible inflammation
and that neutrophils potentially represent a quantitative
measure of conjunctival inflammation whether clinically
manifest or not.
The Effects of Topical Glucocorticoids on
Conjunctival Intraepithelial Neutrophils
Systemic glucocorticoids can induce granulocytosis.34 As the
majority of our cross-sectional patients (54% [31/57] at
presentation; 60% ]21/35] at 12 months) were prescribed
topical dexamethasone, it was necessary to determine the
effect of this synthetic glucocorticoid on the presence of
conjunctival neutrophils. This was particularly important given
the raised levels of neutrophils in the conjunctival mucosa of
patients with OcMMP. An additional cohort of seven healthy
volunteers (median age 74 [range, 57–84 years]; four females;
six white European, one South Asian) were sampled before and
4 weeks after cataract surgery. Participants were instructed to
use topical dexamethasone 0.1% every 6 hours during the
postoperative follow-up period. This enabled a comparison of
leukocyte numbers in an uninflamed eye with and without the
application of topical steroids. The 4-week review samples
were taken only if the following criteria were met: Cataract
surgery was uncomplicated; there was no evidence of ocular
surface or intraocular surface inflammation at 4 weeks post
surgery. There was no significant difference in the
CD45INTCD11bþCD16þCD14 neutrophil populations before
and after the use of topical treatment (13 vs. 0, P¼ 0.06; 1.7%
vs. 0%, P¼ 0.13), although the trend suggested a reduction in
the numbers present on the ocular surface (Supplementary Fig.
S1). We were able to conclude that the use of topical
dexamethasone in the OcMMP cohort was unlikely to have
contributed to changes in observed in the conjunctival
granulocyte population.
Conjunctival Neutrophils Correlate With
Progressive Conjunctival Scarring and Inferior
Forniceal Foreshortening Measured With the FDM
in OcMMP
A longitudinal cohort of 35 OcMMP patients (Table 2) were
followed for a year and reviewed at baseline (Supplementary
Table S2) and at 3, 6, 9, and 12 months (Supplementary Table
S3). By 12 months, there had been progression of scarring
(measured by central depth) in the lower fornix in 53% of eyes,
resulting in a median depth of 3 (0–8) mm, representing a
significant reduction in lower fornix depth (P < 0.001).
TABLE 3. Conjunctival Leukocyte Populations in Healthy Controls, PSS, and OcMMP
Cell Population Healthy PSS OcMMP Kruskal-Wallis Dunn’s Post Hoc
Total CD45þ live leukocytes 766.3 1041 1504 0.53, NS NS
Leukocyte subsets
Lymphocyte numbers 684 849 772 0.20, NS NS
Lymphocytes % of leukocytes 73.0 65.1 35.6 <0.0001 H vs. M‡, P vs. M‡
Monocyte numbers 107 204 229 0.12, NS NS
Monocytes % of leukocytes 7.00 15.0 10.7 0.12, NS NS
Neutrophil numbers 5.80 1.80 109 <0.0001 H vs. M‡, P vs. M‡
Neutrophils % of leukocytes 0.800 0.200 18.1 <0.0001 H vs. M‡, P vs. M‡
CD11bþ MFI 374 0 588 0.002 P vs. M†
T-cell numbers 436 686 312 0.005 P vs. M†
T cells % of lymphocytes 69.9 70.8 53.7 <0.0001 H vs. M†, P vs. M‡
CD8abþ numbers 371 445 124 0.0001 H vs. M†, P vs. M‡
CD8abþ % of T cells 76.0 61.5 50.0 0.0008 H vs. M‡
CD8abþ CD45ROþ % 92.7 96.1 94.6 0.10, NS NS
CD4þ numbers 38.2 199 50.3 0.05, NS NS
CD4þ % of T cells 10.7 25.2 24.5 0.02 H vs. M*
CD4þCD45ROþ % 100 100 100 0.88, NS NS
CD4:CD8 ratio 0.150 0.400 0.500 0.003 H vs. M†
DN cell, CD4CD8 numbers 13.9 52.9 34.0 0.07, NS NS
DN % of T cells 5.40 7.90 17.5 0.0006 H vs. M‡
CD8aaþ numbers 8.00 20.1 12.6 0.17, NS NS
CD8aaþ % of T cells 1.80 4.60 7.05 0.01 H vs. M†
B cell, CD19þCD20þ numbers 18.5 43.2 17.6 0.32, NS NS
B cell % of lymphocytes 2.50 2.70 4.40 0.4, NS NS
NK cell, CD3CD56þ numbers 46.5 60.2 49.5 0.48, NS NS
NK cells % lymphocytes 6.90 5.60 7.90 0.62, NS NS
NKT cell, CD3þCD56þ numbers 31.5 43.9 18.6 0.02 P vs. M*
NKT cells % lymphocytes 5.10 6.30 2.90 0.14, NS NS
Comparisons were undertaken by comparing the most inflamed eye in patients with MMP (M) versus the right eye of healthy participants (H)
and patients with PSS (P). Median values are shown and comparisons were undertaken by the Kruskal-Wallis test with Dunn’s post hoc analysis. DN,
double negative; NK, natural killer; NS, not significant.
* P ¼ 0.01 to 0.05.
† P ¼ 0.001 to 0.01.
‡ P < 0.001.
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Similarly, the median central upper fornix depth had contract-
ed in 47% of eyes (P < 0.01). The number and extent/width of
symblephara had also progressed (number: lower, P ¼ 0.02;
upper, P < 0.001; extent/width: lower, P < 0.001; upper, P <
0.001); and Tauber scoring had increased in 67% of eyes at 12
months.
Given the raised neutrophils, reduction in CD8 abþ T cells,
and raised CD4:CD8 ratio when comparing MMP to controls
(HC and pSS), comparisons among cell populations at baseline
and disease progression (measured by an increase in conjunc-
tival scarring) were determined. Neutrophil numbers and
percentage were significantly elevated in the group that
FIGURE 3. Epithelial neutrophils are present even in clinically uninflamed eyes despite the severity of clinically identifiable conjunctival
inflammation correlating with the inflammatory infiltrate. (A) Representative flow plots for CD45INTCD14 live granulocytes for a healthy
individual, a patient with a clinically uninflamed eye, one with mild, and one with moderate clinical inflammation. Healthy and clinically uninflamed
individuals were also compared ([B] OcMMP n¼ 20, HC n¼ 21). The number and percentages of neutrophils were correlated with the degree of
conjunctival inflammation and healthy participants (C). Two-group comparison with the Mann-Whitney U test and ordinal group comparisons were
undertaken by the Jonckheere-Terpstra test (NS, not significant; *P ¼ 0.01–0.05; **P ¼ 0.001–0.01; ***P < 0.001).
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progressed compared to the group that did not according to
lower fornix shrinkage (143 [2–36,636] vs. 27 [1–5910], Mann-
Whitney U test P ¼ 0.004; and 10% [0.1–74] vs. 3.7% [0–71],
Mann-Whitney U test P ¼ 0.04) (Fig. 4B). In light of the
significant changes seen in the increased neutrophils (total
numbers and percentage), a GEE was undertaken to account
for the effects of correlation between the right and left eyes. A
moderate degree of correlation was observed between the
right and the left eyes (correlation value ¼ 0.376). Further-
more, the number of neutrophils was found to be 128 in the
eyes that demonstrated progression of disease versus 39 (P <
0.001) in the nonprogression group, confirming the test
statistic using the Mann-Whitney U test. The percentage of
neutrophils was also confirmed as significantly higher among
eyes that progressed using the GEE (correlation value¼ 0.605;
10% vs. 5%; P¼0.02). By contrast, the levels of CD8 abþ T cells
and the CD4:CD8 ratio were not different among those with
and without evidence of lower fornix shrinkage (139 [39%] vs.
97 [45]; P ¼ 0.75 and 0.6 vs. 0.4; P ¼ 0.32, respectively).
There was no significant difference in the number/
percentage of neutrophils among eyes that progressed versus
those that did not progress according to upper fornix depth
parameters (49 [4%] vs. 69 [12%]; P¼ 0.56). Similarly, this was
also the case for the CD8 abþ T-cell population (124 [27%] vs.
138 [28%]; P¼ 0.8) and CD4:CD8 ratio (0.5 vs. 0.6; P¼ 0.98),
indicating that quantification of neutrophil inflammatory
infiltrate, CD8 abþ T-cell populations, or CD4:CD8 ratios did
not predict upper fornix shrinkage during this study period.
Comparable findings were seen when assessing progression by
Tauber staging in this cohort. Comparing eyes that progressed
with those that did not, there was no significant difference in
the number/percentage of neutrophils (49 [6%] vs. 41 [4%]; P
¼ 0.27), CD8 abþ T-cell population (114 [40%] vs. 144 [52%]; P
¼ 0.36) and CD4:CD8 ratio (0.6 vs. 0.2; P¼ 0.08). In summary,
FIGURE 4. Neutrophil numbers and percentage are significantly higher among eyes that develop lower fornix shrinkage in OcMMP, are maintained
over time; and in clinically uninflamed eyes, the number of neutrophils correlates with the degree of central lower fornix shrinkage in OcMMP.
Assessment of central lower fornix with a fornix depth measurer (FDM) is shown in (A). Comparisons between the conjunctival
CD45INTCD11bþCD16þCD14 neutrophil numbers and percentage of leukocytes were undertaken in a cohort of 35 patients with OcMMP by
the Mann-Whitney U test (NS, not significant; *P¼0.01–0.05; **P¼0.001–0.01). The median neutrophil numbers and percentage are shown for eyes
that did not (No Prog) and did progress (Prog) (B). Changes over time were calculated by using a generalized estimating equation (GEE) at 0, 3, 6, 9,
and 12 months follow-up for right and left eyes. This is represented schematically for the median neutrophil numbers over time ([C] left and right
columns, respectively). The number and percentage of neutrophils were compared by DFDM (the change in central lower fornix measured in
millimeters between 0 and 12 months; FDM at 12 months FDM at 0 months) (D). ROC curve analysis for neutrophil numbers and percentage are
shown in (E) (n¼ 69 eyes). Comparisons were undertaken by the Jonckheere-Terpstra test (NS, not significant; *P¼ 0.01–0.05). FDM, fornix depth
measurer.
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increased neutrophils at baseline were seen in eyes that went
on to develop lower fornix shrinkage, as measured with an
FDM.
As raised conjunctival epithelial neutrophils seen in patients
with OcMMP at baseline were more likely to result in lower lid
fornix depth shrinkage, changes over time were examined. In
order to verify if this inflammatory infiltrate persisted over
time, a GEE was employed. Neutrophil numbers at 0, 3, 6, 9,
and 12 months were unaltered, with no significant difference
seen over this follow-up period (P¼ 0.46), and no change was
observed in neutrophil percentage (P ¼ 0.76). A schematic
demonstrating the median neutrophil numbers over time for
the right and left eyes is shown in Figure 4C. This suggests that
the conjunctival inflammatory neutrophil infiltrate is constant
in OcMMP and that treatment protocols are suboptimal.
Having determined that an inflammatory infiltrate with
neutrophils was present in patients with OcMMP and that this
infiltrate was present even among those without evidence of
inflammation on clinical examination, it was important to
determine whether this finding could predict progression of
fibrosis measured by reduction in fornix depth. Subgroup
analysis among clinically uninflamed eyes (patients with
uninflamed eyes examined at 12 months; n ¼ 14) was
undertaken, which showed that the change in lower lid fornix
depth (DFDM) correlated with the number of neutrophils (P¼
0.035; Jonckheere-Terpstra test) but not by percentage (P ¼
0.85; P ¼ 0.52) (Fig. 4D).
In order to determine a cutoff value for inflamed and
noninflamed neutrophilia, an increased population of neutro-
phils in the conjunctiva was defined by using the median
number of neutrophils (44) determined in the uninflamed
group at cross-sectional analysis at baseline. A count of >44
neutrophils was considered elevated, and those with <44
neutrophils were deemed not to be elevated. As a means of
predicting progression among all eyes, the presence of
conjunctival neutrophils in OcMMP uninflamed eyes conferred
a sensitivity of 75%, a specificity of 70%, and positive predictive
value 73%. Neutrophils as a percentage of total leukocytes, that
is, 6%, defined a sensitivity of 64%, a specificity of 66%, and
positive predictive value of 68%. Receiver operating character-
istic curve analysis shows an area of 0.7 (P < 0.01) and 0.64 (P
¼ 0.046), respectively (Fig. 4E). An alternative means of
addressing this question was undertaken by comparing
progression among eyes with no inflammation (n ¼ 14) with
a raised neutrophil count against those without raised
neutrophils. Progression rates were found to be significantly
higher among those with a greater neutrophil infiltrate (P ¼
0.02; Fisher’s exact test), even when uninflamed. These data
taken together indicate that progression of conjunctival fibrosis
is more likely with an elevation in the number of conjunctival
epithelial neutrophils.
DISCUSSION
‘‘Hidden’’ conjunctival inflammation in OcMMP provides a
major challenge for the clinician. Progressive shrinkage of the
conjunctival fornices occurs in up to 50% of patients despite
immunosuppression perceived to be adequate in curbing the
clinical inflammatory response. In this study, we have
demonstrated the presence of a conjunctival epithelial
infiltrate characterized predominantly by neutrophils in the
ocular mucosa of patients with OcMMP at baseline and shown
that persistently raised neutrophils were associated with
progressive conjunctival fibrosis, even in the absence of
clinically visible inflammation. Importantly, these changes
could be detected by longitudinal sampling using a minimally
invasive technique, OSIC, currently accepted diagnostically in
combination with immunohistochemistry for phenotyping
corneal and conjunctival cells in ocular surface metaplasia
and failure. Whereas our laboratory outcome measure for
determining a biomarker of disease activity and progression
was profiling leukocytes with flow cytometry, OSIC opens the
arena to other putative laboratory readouts including ocular
surface genomics, proteomics, lipidomics, and microbiome
analyses. Commercially available devices such as the Eyeprim
(Opia Technologies, Paris, France) are now available to simplify
OSIC using a Supor 200 polyethersulfone filter and allow
nonmedically trained staff to sample the ocular surface.
We analyzed cells recovered from OSIC with flow
cytometry to confirm an inflammatory cellular infiltrate within
the suprabasement membrane conjunctival epithelium in
OcMMP compared to healthy participants. This cellular
infiltrate differed from that in patients with pSS who have
slowly progressive conjunctival scarring disease. Previous
histology-based studies have shown that in conjunctival tissue
sections from OcMMP patients who have evidence of minimal
but clinically visible inflammation,8,9,12 there is predominately
a T-cell infiltration of the conjunctival stroma and neutrophils
in the epithelium (with a CD4:CD8 ratio of 0.5).8,9 These
studies also included patients in receipt of topical glucocorti-
coids at the time of biopsy, suggesting that therapy had not
selectively depleted lymphocytes.8,9 In severe conjunctival
inflammation, the CD4:CD8 ratio increases to 1.0,8,9 which
reflects an increase in CD4þ T cells, a finding that is also seen
in human and murine models of pSS.8,33,35,36 A murine model
does not currently exist for OcMMP, and studies have been
restricted to human tissue. A series of 10 conjunctival biopsy
samples has confirmed an elevation of Th17 cells in OcMMP
compared to HC.37 In our study, there was a trend toward
raised numbers of CD4þ T cells in both MMP and pSS, and the
major influence on the increased CD4:CD8 ratio was a
reduction in CD8abþ T cells. We have previously shown that
CD8 abþ T cells are in fact effector memory, mucosal homing,
cytotoxic lymphocytes, capable of recognizing herpetic
viruses.16 Whether this represents an alteration in the effector
function of these cells in progressive conjunctival scarring
processes such as OcMMP, or simply reflects abnormal
architecture of the ocular surface secondary to scarring,
remains to be explored. A reduction in CD8abþ T cells has
previously been described in chronic patients with Stevens
Johnson Syndrome-Toxic Epidermal Necrolysis (SJS-TEN),
although direct comparisons with current and published data
are precluded because of the significant age difference
between these two disease groups and the fact that conjunc-
tival leukocyte profiles are known to be, in part, dependent on
age.31
In addition to T cells, increased neutrophils have been
reported in tissue analyses of OcMMP patients with severe
conjunctival inflammation,8,9 and this evidence supports our
data examining epithelial infiltrate with OSIC-flow cytometry
from clinically inflamed eyes. Importantly, we have also
demonstrated an increase in the percentage of neutrophils in
OcMMP clinically uninflamed eyes—a finding not seen in
either our disease control cohort of patients with pSS (who had
equivalent dry eye disease to our OcMMP cohort with minimal
conjunctival fibrosis) or HC. It is unlikely that the use of topical
steroids or antiglaucoma agents confounded the presence of
neutrophils in our cohort. Our validation study on healthy
patients administering dexamethasone every 6 hours for 4
weeks demonstrated no increase in conjunctival neutrophil
population in the validation time period. It is unlikely that
glucocorticoids selectively spared neutrophils by reducing
lymphocyte numbers in the OcMMP group. While the
percentages were reduced, the increase in neutrophils would
account for this, as the absolute numbers of lymphocytes (684
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vs. 849 vs. 772; P ¼ 0.20 [NS] and leukocytes (766.3 vs. 1041
vs. 1504; P ¼ 0.53 [NS]) were consistent among groups.
Similarly, it is unlikely that topical antiglaucoma medication
had a neutrophil chemoattractant effect, as only three patients
in our cohort required ocular hypotensive therapy.
Our data confirm that the neutrophils present in the
conjunctival epithelium correlate with the grade of clinical
inflammation and persist in an eye without visible conjunctival
inflammation. This finding is supported by previous OSIC-flow
data in SJS-TEN patients31 (who have an OcMMP-like conjunc-
tival scarring phenotype), and tear ELISA analysis, where
neutrophil collagenase matrix metalloproteinase (MMP)-8 and -
9 together with myeloperoxidase have been detected in
patients with both SJS-TEN and OcMMP.38 Most importantly,
our novel finding demonstrates that eyes with an increase in
conjunctival epithelial neutrophils at baseline had evidence of
fornix shrinkage at 12 months follow-up. The presence of
neutrophils could potentially perpetuate fibrotic signaling
cascades and support a role for innate inflammatory cells as
a basis for progression of disease in conjunctival scarring
disorders39 or shaping the adaptive immune response.40
The importance of the complement-mediated component
in the inflammatory process in OcMMP has previously been
emphasized,41 with antibodies inducing the classical comple-
ment cascade via C3, leading to chronic recruitment of
neutrophils to the conjunctival BMZ. The precise reason for
neutrophil accumulation in the conjunctiva of patients with
OcMMP as opposed to pSS is unclear. In both conditions,
dysregulation of CD4þ T cells, including an elevation of IL-17
subsets, is seen.37,42 In OcMMP, the complement cascade is
activated at the BMZ in response to autoantibodies. Presum-
ably this involves the classical pathway via IgG binding to
C1q, resulting in the BMZ being coated in C3b. Although
murine models suggested that the complement cascade was
not involved in subepithelial lesions in skin, closer scrutiny of
the mouse conjunctiva has not been undertaken.43 The
murine ocular surface may or may not have had evidence of
blistering, but in humans, this again is not a prominent
feature; scarring takes place without gross evidence of blister
formation. It is therefore quite possible that autoimmune-
mediated recruitment of complement contributes to the
inflammatory infiltrate in turn by recruiting neutrophils. This
may be compounded by recruitment of other cells to the
inflammatory environment within the conjunctiva as in other
mucosal sites. Indeed, CD4þ T cells have been shown to
regulate neutrophil recruitment to the site of inflammation in
a mouse colitis model.44
The absence of detectable coexisting infection suggests
that this may be a potential mechanism for chronic
neutrophil elevation or an undetectable alteration in the
diseased ocular microbiome driving the immune response.45
In a fungal model of keratitis, neutrophils demonstrate
increased elastase and MMP-9 activity via autocrine produc-
tion of IL-17 in response to IL-6 and IL-23.46,47 In addition, in
cystic fibrosis, pseudomonal infection induces a persistent
elevated inflammatory response to IL-17. Abrogating IL-17
prior to infection in mice has been shown to improve
outcome, suggesting hyperresponsiveness to infection in the
airways of patients and consequent damage via neutrophils.48
Bullous pemphigoid (an immunobullous disease affecting the
skin), shares target antigens to circulating autoantibodies in
the BMZ, for example, BP180.1,49,50 Neutrophil elastase
induces subepithelial blisters in a murine model of this
disease, with elastase-deficient mice being resistant to
subepithelial blistering.51 Neutrophil serine proteases may
also play a role in fibrosis. Mice lacking neutrophil elastase,
for example, have been shown to be resistant to pulmonary
fibrosis52; and in cryptogenic fibrosing alveolitis, an elevation
of neutrophil numbers and elastase is seen in tissue
compared to the clinically less severe fibrotic process evident
in systemic sclerosis.53 The neutrophil collagenase MMP-8
has also been shown to induce fibrosis in a bleomycin lung
injury model,54 and neutrophil extracellular trap (NET)
formation in respiratory mucosa has been associated with
lung myofibroblast differentiation and scar formation.55
Neutropenic mice have been shown to have low scarring
potential and accelerated wound healing.56 Furthermore, the
presence of NETs has been detected in ocular surface
disease.57 Together, these data suggest the putative role for
neutrophils in profibrotic inflammatory processes that have
the potential to persist and drive adaptive immune response
in OcMMP. The relative contributions of an altered ocular
surface microbiome secondary to cicatrization, autoimmune-
driven complement activation of neutrophils, or both have
yet to be determined.
Limitations in this study include an inability to account for
different immunosuppressive strategies on the effects of
neutrophils (these included prednisolone, dapsone, mycophe-
nolate, methotrexate, rituximab, cyclophosphamide, and com-
binations thereof) over the study period. Subgroup comparison
and correlation with progression and neutrophil numbers were
therefore beyond the scope of this study. It would also be
interesting in future validation studies to attempt quantification
and potentially include a positive control group that facilitates
studying the effect of topical glucocorticoids before and after
their introduction in conjunctival inflammation.
These data, however, confirm that subclinical inflammation
takes place in OcMMP, sometimes despite the introduction of
systemic immunosuppression, irrespective of its mode of action.
This inflammatory process is characterized by a conjunctival
neutrophilia, and this can be determined in a minimally invasive
fashion through OSIC-flow. An increase in conjunctival neutro-
phils confers a greater chance of disease progression despite a
failure to determine disease activity at a clinical level, that is,
through observing conjunctival hyperemia. This failure to detect
this inflammatory process facilitates a chronic, even low-grade,
elevation in neutrophils. Crucially it is the inability to
circumvent neutrophil elevation that promotes fibrosis. The
maintenance of an otherwise undetectable underlying inflam-
matory process can lead to cicatrization, irrespective of a further
elevation during the course of the study.
In summary, our data show the potential for OSIC combined
with multicolor flow cytometry to determine epithelial
neutrophils as a disease biomarker,58 with a positive predictive
value in the region of 70%. Having a minimally invasive test
available in the clinic to detect ‘‘invisible’’ ocular surface
inflammation could provide a major improvement in monitor-
ing disease activity, especially when considering patients who
have a clinically uninflamed eye. Selected and effective
immunomodulatory targeting of patients at greater risk of
progressive conjunctival scarring based upon detection and
quantification of neutrophils could not only provide cost-
effective biomarker-guided treatment but also hugely benefit
patients who have potentially blinding OcMMP. Neutrophil-
specific or persistent innate response drug targeting may be
advantageous in the future development of therapeutics for the
management of OcMMP.
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